SCHEMBL2920070

SCHEMBL2920070

CON=C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethane SCHEMBL21591806 0.69
SCHEMBL10764211 0.67
SCHEMBL555067 0.67
SCHEMBL28369351 0.67
SCHEMBL132008 0.64
Hydrochloric Acid SCHEMBL29148029 0.64
SCHEMBL132007 0.64
SCHEMBL14098372 0.62
SCHEMBL2918378 0.62
SCHEMBL2919918 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112552312-A Synthetic method of Ruogeli or salt thereof 杭州科巢生物科技有限公司 2021-03-26 CN claimed
US-20070060558-A1 Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents PALUMED S.A. (FR) 2007-03-15 US claimed
US-11447445-B2 Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2022-09-20 US disclosed
CN-112552312-B Synthetic method of Ruogeli or salt thereof 杭州科巢生物科技有限公司 2022-08-05 CN disclosed
CN-112552312-A Synthetic method of Ruogeli or salt thereof 杭州科巢生物科技有限公司 2021-03-26 CN disclosed
US-20140030784-A1 Terpene Synthases and Methods of Using the Same UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2014-01-30 US disclosed
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
CN-101035769-A Pyrimidine urea derivatives as kinase inhibitors NOVARTIS AG (CH) 2007-09-12 CN disclosed
US-20070060558-A1 Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents PALUMED S.A. (FR) 2007-03-15 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed
WO-2004014425-A1 ACTIVATORS OF SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNELS AND USE THEREOF GLAXO GROUP LIMITED (GB) 2004-02-19 WO disclosed
EP-0763043-A1 PROCESS FOR THE PREPARATION OF TRIHYDRATED CEFIXIME MARCHAM TRADING &amp; INVESTMENT LTD. (IE) 1997-03-19 EP disclosed
WO-1995033753-A1 PROCESS FOR THE PREPARATION OF TRIHYDRATED CEFIXIME MARCHAM TRADING & INVESTMENT LTD. (IE) 1995-12-14 WO disclosed
US-5200403-A Inhibition of βlactamase with 6 β-(substituted methyl)-penicillanic acid derivatives FARMITALIA CARLO ERBA S.R.L. (IT) 1993-04-06 US disclosed